Taysha Gene Therapies Research and Development Expenses 2020-2024 | TSHA

Taysha Gene Therapies research and development expenses from 2020 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Taysha Gene Therapies Annual Research and Development Expenses
(Millions of US $)
2023 $57
2022 $91
2021 $132
2020 $32
2019 $0
Taysha Gene Therapies Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $15
2024-06-30 $15
2024-03-31 $21
2023-12-31 $13
2023-09-30 $12
2023-06-30 $20
2023-03-31 $13
2022-12-31 $13
2022-09-30 $17
2022-06-30 $24
2022-03-31 $38
2021-12-31 $38
2021-09-30 $40
2021-06-30 $31
2021-03-31 $24
2020-12-31 $12
2020-09-30 $11
2020-06-30 $3
2020-03-31 $6
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.506B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00